Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen

Journal of Medical Virology

Volumn 83, Issue 3, 2011, Pages 377-383

  Lillemark, Marie Rathcke ^a   Gerstoft, Jan ^b   Obel, Niels ^b,c   Kronborg, Gitte ^d   Pedersen, Court ^e   Jørgensen, Louise Bruun ^a   Madsen, Tina Vasehus ^a   Katzenstein, Terese Lea ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Gag CS; PI plasma concentrations; Resistance; Ritonavir

Indexed keywords

ATAZANAVIR; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA CLEAVAGE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION; VIROLOGICAL FAILURE; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DENMARK; DRUG RESISTANCE, VIRAL; FEMALE; GENES, GAG; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PROTEASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78851472529     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21997     Document Type: Article

References (37)

1. Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K, Staccato Study Team. 2006. Absence of resistance mutations in antiretroviral-naïve patients treated with ritonavir-boosted Saquinavir. Antivir Ther 11: 631-635.
2. Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H. 2009. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J Virol 83: 3059-3068.
3. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. 1990. An inhibitor of the protease blocks the maturation of human and simian immunodeficiency viruses and the spread of infection. PNAS 87: 7472-7476.
4. Bally F, Martinez R, Peters S, Sudre P, Telenti A. 2000. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 16: 1209-1213.
5. Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA, Haubrich RH. California Collaborative Treatment Group 578 Study Team. 2007. A randomized controlled trial of therapeutic drug monitoring in treatment-naïve and experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 46: 433-442.
6. Borman AM, Paulos S, Clavel F. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors. Selection of resistance mutations in the presence and absence of the drug. J Gen Virol 77: 419-426.
7. Cooper CL, van Heewijk RP, Gallicano K, Cameron DW. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36: 1585-1592.
8. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71: 1089-1096.
9. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70: 3763-3769.
10. Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, Gorelick RJ, Mardy S, Tang C, Summers MF, Mitsuya H. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 277: 5952-5961.
11. Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Norton M, Delfraissy JF, Rouzioux C, Chaix ML. 2009. Baseline number of substitutions in p2/NC site of Gag gene is predivtive of virological failure in patients randomized to first-line Lopinavir/ritonavir single drug regimen: Week 96 results of the Monark trial. 16th conference on retroviruses and opportunistic infections (CROI).
12. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemisty 34: 9282-9287.
13. Hicks C, King MS, Gulick RM, White AC, Jr., Eron JJ, Jr., Kessler HA, Benson C, King KR, Murphy RL, Brun SC. 2004. Long-term safety and durable antiretroviral activity of Lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 18: 755-779.
14. Justesen US, Pedersen C, Klitgaard NA. 2003. Simultaneous quantitative determination of the HIV protease inhibitors Indinavir, amprenavir, ritonavir, Lopinavir, Saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 783: 491-500.
15. Justesen US. 2006. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy. Basic Clin Pharmacol Toxicol 98: 28-31.
16. Jorgensen LB, Christensen MB, Gerstoft J, Mathiesen LR, Obel N, Pedersen C, Nielsen H, Nielsen C. 2003. Prevalence of drug resistance mutations non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 35: 800-807.
17. Katz R, Skalka A. 1994. The retroviral enzymes. Annu Rev Biochem 63: 133-173.
18. Leitner T, Escanilla D, Marquina S, Wahlberg J, Broström C, Hansson HB, Uhlén M, Albert J. 1995. Biological and molecular characterization of subtype D, G and A/D recombinant HIV-1 transmissions in Sweden. Virology 209: 136-146.
19. Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR. 2008. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 198: 51-58.
20. Liu TF, Shafer RW. 2006. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618. Epub 2006 Apr 28.
21. Loeb DD, Hutchinson CA, III, Adgell MH, Farmerie WG, Swanstrom R. 1989. Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases. J Virol 63: 111-121.
22. Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, Pedersen C, Larsen CS, Møller A, Willumsen L, Obel N. 2005. Demographics of HIV-1 infection in Denmark: Results from the Danish HIV Cohort Study. Scand J Infect Dis 37: 338-343.
23. Madsen TV, Leitner T, Lohse N, Obel N, Ladefoged K, Gerstoft J, Petersen AB, Nielsen C, Jørgensen LB. 2007. Introduction of HIV-1 into an isolated population: Molecular epidemiologic study from Greenland. AIDS Res Hum Retroviruses 23: 675-681.
24. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG. 2007. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 54: 367-374.
25. Mammano F, Petit C, Clavel F. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 72: 7632-7637.
26. Mammano F, Trouplin V, Zennou V, Clavel F. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol 74: 8524-8531.
27. Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chêne G, Raffi F, Brun-Vézinet F. APROCO/COPILOTE Study Group. 2005. Intermittent viremia during first-line, protease inhibitors-containing therapy: Significance and relationship with drug resistance. J Clin Virol 33: 75-78.
28. McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, Sawyer TK, Heinrikson RL, Tarpley WG. 1990. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247: 454-456.
29. Moyle GJ, Back D. 2001. Principles and practice of HV-protease inhibitor pharmacoenhancement. HIV Med 2: 105-113.
30. Myint L, Matsuda M, Matsuda Z, Yokomaku Y, Chiba T, Okano A, Yamada K, Sugiura W. 2004. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistance human immunodeficiency virus type 1. Antimicrob Agents Chermother 48: 444-452.
31. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13: 2349-2359.
32. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4: e36.
33. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. 2004. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 78: 12446-12454.
34. Verheyen J, Litau E, Sing T, Däumer M, Balduin M, Oette M, Fätkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R. 2006. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6 in therapy-naïve and therapy-experienced patients. Antivir Ther 11: 879-887.
35. von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF, for the Swiss HIV Cohort Study. 2007. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment a comparison of different regimen types. Arch Intern Med 167: 1782-1790.
36. Zazzi M. 2007. Lack of major resistance mutations in HIV-1 protease at failure of boosted protease inhibitor-based firstline antiretroviral treatment. Rev Antivir Ther 2: 4-12.
37. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. 1997. Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J Virol 71: 6662-6670.